DFN-15 Active

DRUG2 trials

Sponsors

BioDelivery Sciences International

Conditions

Migraine Headache

Phase 3

Efficacy, Tolerability, and Safety Study of DFN-15

CompletedNCT03006276

BioDelivery Sciences InternationalMigraine Headache

Start: 2016-12-31End: 2019-05-31Updated: 2023-01-10

Efficacy, Tolerability, and Safety of DFN-15

CompletedNCT03009019

BioDelivery Sciences InternationalMigraine Headache

Start: 2016-12-31End: 2019-05-31Updated: 2023-01-10

Related Papers

Impact of Celecoxib Oral Solution on Symptomatic Improvements in the Acute Treatment of Migraine (P15-2.006)

Neurology2022-05-031 citations

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Tolerability, and Safety of Celecoxib Oral Solution (ELYXYB) in Acute Treatment of Episodic Migraine with or without Aura

Journal of Pain Research2021-08-0118 citations

Efficacy and safety of DFN-15, an oral liquid formulation of celecoxib, in adults with migraine: a multicenter, randomized, placebo-controlled, double-blind, crossover study

Neuropsychiatric Disease and Treatment2017-11-017 citations